Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Ultragenyx Faces Securities Lawsuit...
Business securities lawsuit

Ultragenyx Faces Securities Lawsuit Over Failed Drug Trials

Analysis based on 121 articles · First reported Feb 05, 2026 · Last updated Apr 08, 2026

Sentiment
-60
Attention
4
Articles
121
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the news of Ultragenyx's failed drug trials, leading to a significant drop in its stock price. The subsequent class action lawsuits by firms like Kahn Swick & Foti and Faruqi & Faruqi further highlight investor concerns and potential financial liabilities for Ultragenyx.

Biotechnology Legal Services
Event Summary

Ultragenyx Pharmaceutical Inc. is facing a class action securities lawsuit filed by Kahn Swick & Foti and Faruqi & Faruqi. The lawsuit alleges that Ultragenyx made false and misleading statements regarding its Phase III Orbit and Cosmic studies for setrusumab, a drug for Osteogenesis Imperfecta. On December 26, 2025, Ultragenyx announced that both studies failed to achieve a statistically significant reduction in annualized fracture rates, leading to a 42% drop in its stock price. The company is now evaluating operations and planning significant expense reductions. The lawsuit covers investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025, and is pending in the United States===United States District Court for the Northern District of California.

Key Actions
100 Kahn Swick & Foti notified investors of a class action securities lawsuit Ultragenyx
100 Ultragenyx allegedly made false and misleading statements
100 Ultragenyx announced failed Phase III study results for setrusumab
95 Ultragenyx experienced a 42% stock price drop
95 Ultragenyx stock price fell by approximately 42%
90 Kahn Swick & Foti filed a securities class action lawsuit Ultragenyx
90 Rosen Law Firm filed class action lawsuit Ultragenyx
90 Kahn Swick & Foti notified investors of class action securities lawsuit Ultragenyx
+ 3 more actions View on Dashboard
Entities Involved
stock
Ultragenyx
Ultragenyx is facing a class action securities lawsuit due to alleged misleading statements regarding its Phase III Orbit and Cosmic studies for setrusumab. The failure of these studies to achieve statistical significance led to a significant drop in its stock price and plans for expense reductions. The lawsuit seeks to recover losses for investors affected by the alleged securities fraud.
Importance 100 Sentiment -80
stock
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical is facing a securities class action lawsuit due to alleged failure to disclose material information regarding its Phase III Orbit and Cosmic studies for setrusumab. The failure of these studies led to a significant 42% drop in its share price, and the company is evaluating expense reductions.
Importance 100 Sentiment -70
priv
Kahn Swick & Foti
Kahn Swick & Foti, a prominent securities litigation law firm, is representing investors in the class action lawsuit against Ultragenyx. The firm is actively seeking lead plaintiffs and informing affected investors about their legal rights.
Importance 80 Sentiment 70
priv
Rosen Law Firm
Rosen Law Firm is representing purchasers of Ultragenyx common stock in a class action lawsuit, reminding investors of the lead plaintiff deadline. The firm is actively seeking to recover damages for investors who suffered losses due to the alleged misleading statements by Ultragenyx.
Importance 80 Sentiment 20
priv
The Gross Law Firm
The Gross Law Firm is initiating and representing shareholders in a securities class action lawsuit against Ultragenyx, seeking recovery for investors who incurred losses.
Importance 70 Sentiment 50
priv
The Schall Law Firm
The Schall Law Firm is also reminding investors of a class action lawsuit against Ultragenyx Inc. for violations of securities laws. They are encouraging affected shareholders to contact the firm before the lead plaintiff deadline.
Importance 70 Sentiment 20
priv
Faruqi & Faruqi
Faruqi & Faruqi is another national securities law firm involved in the class action lawsuit against Ultragenyx, detailing the allegations of false and misleading statements made by the company's executives.
Importance 50 Sentiment 60
+ 9 more entities View on Dashboard
Relationships
Kahn Swick & Foti related ↔ Ultragenyx
Faruqi & Faruqi related ↔ Ultragenyx
Lewis Kahn related ↔ Kahn Swick & Foti
Charles Foti related ↔ Kahn Swick & Foti
Ultragenyx related ↔ Kahn Swick & Foti
Ultragenyx related ↔ The Gross Law Firm
Steven Bailey related ↔ Kahn Swick & Foti
Charles C. Foti Jr. related ↔ Kahn Swick & Foti
Ultragenyx Pharmaceutical related ↔ Kahn Swick & Foti
Rosen Law Firm related ↔ Ultragenyx
+ 6 more relationships View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.